Advancing the Science of ctDNA and CTC-Based Diagnostics Across Cancer Types
We’re proud to be featured in five recent publications in the Journal of Liquid Biopsy, the official journal of the International Society of Liquid Biopsy (ISLB). These peer-reviewed studies highlight 1Cell.Ai’s growing impact in translational cancer research and innovation in liquid biopsy-based precision diagnostics.
Each study leverages ctDNA or CTC analysis to uncover critical biomarkers linked to resistance, metastasis, and real-time tumor monitoring across multiple cancers.
1. Early-Stage Breast Cancer: Broader Mutation Detection with ctDNA
ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients.
Read Full Publication
2. CTC Movement Post-Radiotherapy in Pan-Cancer Patients
Transit of Circulating Tumor Cells (CTC) POST radiotherapy at irradiated tumor regions in pan-cancer patients.
Read Full Publication
3. EGFR Mutations & Resistance in Lung Cancer
Downstream effector mutations indicate potential tyrosine kinase inhibitor resistance in EGFR mutated lung cancer patients.
Read Full Publication
4. PD-L1 Expression on CTCs in Pancreatic Cancer
Expression of programmed death-ligand 1 as a dynamic biomarker on circulating tumor cells in pancreatic cancer patients.
Read Full Publication
5. ctDNA + CTC Analysis Correlated with PET Imaging
Comprehensive analysis of ctDNA and CTCs reveals resistance signatures and correlations with PET scan outcomes in cancer patients.
Read Full Publication
These studies reflect 1Cell.Ai’s continued mission to accelerate cancer detection, personalize treatment strategies, and power data-driven oncology through AI, liquid biopsy, and single-cell innovation.